Uterine sarcoma: a retrospective study.
From 1965 to 1982, 86 analyzable patients with uterine sarcoma were treated. Nineteen patients (22%) presented with advanced disease. For the patients with curable diseases (67 patients), the disease-free survivals with a median follow-up of 4.5 years are 40% (surgery only), 53% (surgery + chemotherapy), 46% (surgery + radiation +/- chemotherapy). The local failure rates are 43%: 32%: 33%, respectively. There is no statistical significance. The most important prognostic factor is the clinical extent of the tumor. The role of radiation therapy and chemotherapy will be discussed.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000379:methods; D012189:Retrospective Studies; D012509:Sarcoma / Q000473:pathology / Q000601:surgery*; D014594:Uterine Neoplasms / Q000473:pathology / Q000601:surgery*